As such, future methods that examine forced expression of DcR3 within mouse tumor models may serve to more appropriately represent a human TME and set up LIGHT-based therapies for a successful clinical transition, specifically informing whether a combination with an anti-DcR3 antibody would prevent attenuation of LIGHT functions. The gene discussed is TNFSF14; the disease is neoplasm.